Immunization for HIV-positive individuals

Current Opinion in Infectious Diseases

Volumn 23, Issue 1, 2010, Pages 32-38

  Geretti, Anna Maria ^a   Doyle, Tomas ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Hepatitis; Influenza; Measles; Pneumococcus; Travel

Indexed keywords

AGATOLIMOD; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHOLERA VACCINE; DIPHTHERIA POLIOMYELITIS TETANUS VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; HOV 16 E6E7 ISCOMATRIX VACCINE; INFLUENZA VACCINE; JAPANESE ENCEPHALITIS VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE; RABIES VACCINE; RECOMBINANT HEPATITIS B VACCINE; TICK BORNE ENCEPHALITIS VACCINE; TYPHOID VACCINE; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VIRUS RNA; WART VIRUS VACCINE; YELLOW FEVER VACCINE;

ANAL INTRAEPITHELIAL NEOPLASIA; ANTIBODY RESPONSE; ANTIBODY TITER; ANUS CANCER; ANUS CARCINOMA; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENVIRONMENTAL EXPOSURE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFECTION CONTROL; LIFE EXPECTANCY; OCCUPATIONAL EXPOSURE; PATIENT CARE; PREVALENCE; REINFECTION; REVIEW; RISK REDUCTION; SOCIAL INTERACTION; TRAVEL; TREATMENT RESPONSE; VACCINATION; WELLBEING;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BACTERIAL INFECTIONS; HIV INFECTIONS; HUMANS; VACCINES; VIRUS DISEASES;

EID: 74249095542     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328334fec4     Document Type: Review

References (37)

1. Helfand RF, Witte D, Fowlkes A, et al. Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi. J Infect Dis 2008; 198:1457-1465.
2. Nair N, Moss WJ, Scott S, et al. HIV-1 infection in Zambian children impairs the development and avidity maturation of measles virus-specific immunoglobulin G after vaccination and infection. J Infect Dis 2009; 200:1031-1038.
3. Rigaud M, Borkowsky W, Muresan P, et al. Impaired immunity to recall antigens and neoantigens in severely immunocompromised children and adolescents during the first year of effective highly active antiretroviral therapy. J Infect Dis 2008; 198:1123-1130.
4. Geretti AM. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008; 9:795-848.
5. Mansoor N, Scriba TJ, de Kock M, et al. HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guerin vaccine. J Infect Dis 2009; 199:982-990.
6. Hesseling AC, Cotton MF, Fordham RC, et al. Consensus statement on the revised World Health Organization recommendations for BCG vaccination in HIV-infected infants. Int J Tuberc Lung Dis 2008; 12:1376-1379.
7. Moir S, Malaspina A, Ho J, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008; 197:572-579.
8. Farquhar C, Wamalwa D, Selig S, et al. Immune responses to measles and tetanus vaccines among Kenyan human immunodeficiency virus type 1 (HIV-1)-infected children pre and posthighly active antiretroviral therapy and revaccination. Pediatr Infect Dis J 2009; 28:295-299.
9. GelinckL, Jol-van derZijdeC, Jansen-HoogendijkAM, et al. Restoration of the antibody response upon rabies vaccination in HIV-infected patients treated with HAART. AIDS 2009; 23:2451-2458.
10. Veit O, Niedrig M, Chapuis-Taillard C, et al. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009; 48:659-666.
11. Weinberg A, Huang S, Fenton T, et al. Virologic and immunologic correlates with the magnitude of antibody responses to the hepatitis A vaccine in HIV-infected children on highly active antiretroviral treatment. J AIDS 2009; 52:17-24.
12. Evison J, Farese S, Seitz M, et al. Randomized, double-blind comparative trial of subunitand virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009; 48:1402-1412.
13. Launay O, Grabar S, Gordien E, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J AIDS 2008; 49:272-275.
14. Vigano A, Zuccotti GV, Pacei M, et al. Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. J AIDS 2008; 48:289-296.
15. Burton CT, Goodall RL, Samri A, et al. Restoration of antitetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudy. Clin Exp Immunol 2008; 152:252-257.
16. Puissant-Lubrano B, CombadiFre B, Duffy D, et al. Influence of antigen exposure on the loss of long-term memory to childhood vaccines in HIV-infected patients. Vaccine 2009; 27:3576-3583.
17. Teshale EH, Hanson D, Flannery B, et al. Effectiveness of 23-valent polysaccharide pneumococcal vaccine on pneumonia in HIV-infected adults in the United States, 1998-2003. Vaccine 2008; 26:5830-5834.
18. Gershon AA, Levin MJ, Weinberg A, et al. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J 2009; 28:653-655.
19. Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis 2009; 48:1763-1771.
20. Landrum ML, HullsiekKH,Ganesan A, et al. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2009 [Epub ahead of print].
21. Kim HN, Harrington RD, Crane HM, et al. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. Int J STD AIDS 2009; 20:595-600.
22. Pippi F, Bracciale L, Stolzuoli L, et al. Serological response to hepatitis Bvirus vaccine in HIV-infected children in Tanzania. HIV Med 2008; 9:519-525.
23. Landrum ML, Hullsiek KH, Ganesan A, et al. Hepatitis B vaccine responses in a large US military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009; 27:4731-4738.
24. Cruciani M, Mengoli C, Serpelloni G, et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009; 27:17-22.
25. Bloom A, Jackson K, Kiviat A, Gandhi R. Repeat hepatitis B vaccination may lead to seroprotection in HIV-infected patients who do not respond to an initial series. J AIDS 2008; 50:110-112.
26. de Vries-Sluijs TEMS, Hansen BE, van Doornum GJJ, et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Inf Dis 2008; 197:292-294.
27. Cooper CL, Angel JB, Seguin I, et al. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008; 46:1310-1314.
28. Anema A, Mills E, Montaner J, et al. Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med 2008; 9:57-61.
29. Levin MJ, Song LY, FentonT, et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008; 26:4210-4217.
30. Imaz A, FalcoV, PenarandaM, et al. Impact of prior pneumococcal vaccination on clinical outcomes in HIV-infected adult patients hospitalized with invasive pneumococcal disease. HIV Med 2009; 10:356-363.
31. Rodriguez-Barradas MC, Goulet J, Brown S, et al. Impact of pneumococcal vaccination on the incidence of pneumonia by HIV infection status among patients enrolled in the Veterans Aging Cohort 5-Site Study. Clin Infect Dis 2008; 46:1093-1100.
32. Bliss SJ, O'Brien KL, Janoff EN, et al. The evidence for using conjugate vaccines to protect HIV-infected children against pneumococcal disease. Lancet Infect Dis 2008; 8:67-80.
33. Chen M, Ssali F, Mulungi M, et al. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. Vaccine 2008; 26:4962-4968.
34. Franceschi S, De Vuyst H. Human papillomavirus vaccines and anal carcinoma. Curr Opin HIV AIDS 2009; 4:57-63.
35. Barr E, Sings HL. Prophylactic HPV vaccines: new interventions for cancer control. Vaccine 2008; 26:6244-6257.
36. Chiao EY, Giordano TP, Richardson P, El-Serag HB. Human immunodeficiency virus-associated squamous cell cancer of the anus: epidemiology and outcomes in the highly active antiretroviral therapy era. J Clin Oncol 2008; 26:474-479.
37. Anderson JS, Hoy J, Hillman R, et al. A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. J AIDS 2009; 52:371-381.